Lifileucel Clinical Trials

2 actively recruiting trials across 1 location

▼ -1 trial since May 2026

Also known as: AMTAGVI, LN-144, LN-144/LN-145, TIL, autologous tumor infiltrating lymphocytes, lifileucel, TIL, Tumor-Infiltrating Lymphocytes

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

Iovance Biotherapeutics, Inc.1
Immatics US, Inc.1

Indications

Cancer2
Melanoma, Cutaneous Malignant1
Endometrial Cancer1

Phoenix, Arizona2 trials

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.

Honor Health

Phase 2

SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

Mayo Clinic

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.